Spruce Biosciences/$SPRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
Ticker
$SPRB
Sector
Primary listing
Employees
9
Headquarters
Website
SPRB Metrics
BasicAdvanced
$98M
-
-$84.75
2.44
-
Price and volume
Market cap
$98M
Beta
2.44
52-week high
$240.00
52-week low
$7.26
Financial strength
Current ratio
2.6
Quick ratio
2.033
Long term debt to equity
4.401
Total debt to equity
13.832
Interest coverage (TTM)
-263.89%
Profitability
EBITDA (TTM)
-50.634
Gross margin (TTM)
-2,977.68%
Net profit margin (TTM)
-3,721.17%
Operating margin (TTM)
-3,900.38%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-65.06%
Return on equity (TTM)
-133.62%
Valuation
Price to revenue (TTM)
76.223
Price to book
7.42
Price to tangible book (TTM)
7.42
Price to free cash flow (TTM)
-1.924
Free cash flow yield (TTM)
-51.97%
Free cash flow per share (TTM)
-90.216
Growth
Revenue change (TTM)
-86.43%
Earnings per share change (TTM)
7.34%
3-year earnings per share growth (CAGR)
-15.72%
SPRB News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Spruce Biosciences stock?
Spruce Biosciences (SPRB) has a market cap of $98M as of October 13, 2025.
What is the P/E ratio for Spruce Biosciences stock?
The price to earnings (P/E) ratio for Spruce Biosciences (SPRB) stock is 0 as of October 13, 2025.
Does Spruce Biosciences stock pay dividends?
No, Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders as of October 13, 2025.
When is the next Spruce Biosciences dividend payment date?
Spruce Biosciences (SPRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Spruce Biosciences?
Spruce Biosciences (SPRB) has a beta rating of 2.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.